4d molecular therapeutics ipo12/2/2023 A copy of the final prospectus relating to this offering may be obtained from: Goldman Sachs & Co. Copies of the registration statements can be accessed through the SEC’s website at This offering was made only by means of a prospectus. Registration statements relating to these securities have been filed with the Securities and Exchange Commission (SEC) and became effective on December 10, 2020. LLC, BofA Securities and Evercore ISI acted as book-running managers for the offering. The shares began trading on the Nasdaq Global Select Market on Decemunder the ticker symbol “FDMT.” The aggregate gross proceeds of the offering were approximately $222 million, before deducting underwriting discounts and commissions and other offering expenses. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the closing of its initial public offering of 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price of $23.00 per share. 15, 2020 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics, Inc. ĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000 Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell Microcap Growth IndexĤD Molecular Therapeutics, Inc.EMERYVILLE, Calif., Dec. are subject to a Lock-Up Agreement Ending on. Ĭertain Common Stock of 4D Molecular Therapeutics, Inc. Ĭertain Options of 4D Molecular Therapeutics, Inc. ![]() Enter into License Agreement to Use 4Dmt's Proprietary Intravitreal R100 Vector for Rare Ophthalmic TargetsĬhardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price TargetĬertain Warrants of 4D Molecular Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023ĤD Molecular Says Interim Data of 4D-150 Trial Shows Clinical Activity, Favorable Safety Profile in Wet Age-Related Macular Degeneration PatientsĤDMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023ĤD Molecular Completes Enrollment of Phase 2 Trial in Patients with Wet Age-Related Macular DegenerationĬhardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy RatingĤD Molecular Therapeutics Signs License Agreement With Potential Milestones-Linked Fee Options of up to $942.5 MillionĪstellas Pharma Inc.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |